Thursday, 28 March 2024


GSK gets EU nod for metastatic melanoma inhibitor

24 April 2013 | Regulatory | By BioSpectrum Bureau

Singapore: GlaxoSmithKline has recieved European Commission (EC) marketing authorisation for Mekinist (trametinib) as a single agent in the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Trametinib has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. Trametinib is a MEK inhibitor which blocks the activity of a protein kinase called MEK. This protein is present in the MAPK pathway, which regulates the normal growth and death of cells and plays a role in metastatic melanoma development. Some mutations in the BRAF gene can cause the MEK protein to stimulate cancer cell growth and survival; therefore, inhibiting MEK can potentially slow down the growth of tumours in BRAF-mutant metastatic melanoma.

Dr. Paolo Paoletti, President of Oncology, GSK said, "We welcome the decision of the European Commission. MEK has been pursued as a therapeutic target in cancer for more than a decade, and Mekinist is the first medicine in this class to be licensed in Europe."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account